Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

able to swallow tablets
18 years or older
clinical diagnosis of borderline personality disorder
...
able to swallow tablets
18 years or older
clinical diagnosis of borderline personality disorder
if on psychiatric medication, must be on a stable dose

Exclusion Criteria

current, primary substance abuse, particularly alcoholism
Impaired liver function (> 1.25x the upper limit of the reference range)
history or current psychotic disorder
...
current, primary substance abuse, particularly alcoholism
Impaired liver function (> 1.25x the upper limit of the reference range)
history or current psychotic disorder
Conditions that can affect immune system functioning.
pregnancy
current eating disorder
Participants whose medication has not been stable for more than 4 weeks
suicidal ideation or behavior requiring imminent inpatient treatment

Summary

Conditions
Borderline Personality Disorder
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Basic Science

Participation Requirements

Age
Between 18 years and 50 years
Gender
Only females

Inclusion Criteria

able to swallow tablets
18 years or older
clinical diagnosis of borderline personality disorder
...
able to swallow tablets
18 years or older
clinical diagnosis of borderline personality disorder
if on psychiatric medication, must be on a stable dose

Exclusion Criteria

current, primary substance abuse, particularly alcoholism
Impaired liver function (> 1.25x the upper limit of the reference range)
history or current psychotic disorder
...
current, primary substance abuse, particularly alcoholism
Impaired liver function (> 1.25x the upper limit of the reference range)
history or current psychotic disorder
Conditions that can affect immune system functioning.
pregnancy
current eating disorder
Participants whose medication has not been stable for more than 4 weeks
suicidal ideation or behavior requiring imminent inpatient treatment

Tracking Information

NCT #
NCT02108990
Collaborators
National Center for Advancing Translational Science (NCATS)
Investigators
  • Principal Investigator: Baldwin M Way, Ph.D. Ohio State University Principal Investigator: Jennifer S. Cheavens, Ph.D. Ohio State University
  • Baldwin M Way, Ph.D. Ohio State University Principal Investigator: Jennifer S. Cheavens, Ph.D. Ohio State University